Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Glomerular Hyperfiltration in Non-Diabetic Patients
NCT04143581Phase 2Withdrawn
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Sep 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in chronic kidney disease (CKD) and obesity, sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Measured Glomerular Filtration Rate at 8 weeks. Planned start Sep 2021; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)obesity
Beyond the preview
Go deeper on NCT04143581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143581.